# Update on Emerging Drug Contaminants: Xylazine

Monday, February 27<sup>th</sup>, 2023



Speakers: Claire Zagorski, MSc, LP Graduate Research Assistant, PhARM Program The University of Texas at Austin

MAT ECHO™ Staff: Gloria Miele, PhD, Thomas E. Freese, PhD, Cheryl Ho, MD, and Beth Rutkowski, MPH



# Indigenous Land Acknowledgement

- We respectfully acknowledge that we live and work in territories where Indigenous nations and Tribal groups are traditional stewards of the land.
- Please join us in supporting efforts to affirm Tribal sovereignty across what is now known as California and in displaying respect, honor and gratitude for all Indigenous people.

#### Whose land are you on?

Option 1: Text your zip code to 1-855-917-5263

Option 2: Enter your location at <a href="https://native-land.ca">https://native-land.ca</a>

Option 3: Access Native Land website via QR Code:







What we say and how we say it inspires the hope and belief that recovery is possible for everyone.

Affirming, respectful, and culturally-informed language promotes evidence-based care.

### **PEOPLE FIRST**

### **Language Matters**

in treatment, in conversation, in connection.



### Black Resistance

**\*\*** Smithsonian



BLACK HISTORY MONTH

February 2023



# Update on Emerging Drug Contaminants: Xylazine

### Claire Zagorski, MSc, LP

Graduate Research Assistant, The University of Texas at Austin College of Pharmacy Pharmacy Addictions Research & Medicine Program

@clairezagorski | PhARMprogram.org | @PhARMprogram



### **Disclosures**

#### **FACULTY DISCLOSURE**

UCLA ISAP CME adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with an ACCME-defined ineligible company for anyone who was in control of the content of this activity, except:

Cheryl Ho, MD

Stock or Stock options

Johnson & Johnson Pfizer, Roche, Eli Lilly

All of the relevant financial relationships listed for this individual have been mitigated.



### Learning Objectives

- 1. Recognize three (3) pharmacological effects of xylazine in humans.
- 2. Distinguish two (2) major types of harm caused by xylazine use, in both short and long-term contexts.
- 3. Identify three (3) harm reduction techniques which can be applied to xylazine use.
- 4. Propose two (2) harm reduction approaches to use for xylazine in current practice.







# Drug Users Are Losing Their Fingers and Toes After Shooting 'Tranq Dope'


In Philadelphia, the animal tranquilizer xylazine has infiltrated the opioid supply, and it's been linked to horrific wounds and amputations.





# Wait, What?

- Xylazine a derivative of clonidine
- Alpha-2 agonist
- Used only in animals
- It's probably being diverted (purchased or stolen) from veterinary pharmaceutical suppliers, research labs, and other above-ground sources
- Being added chiefly to heroin/FASH, but also reported in cocaine so far
- No strip test widely available yet, can only be detected with FTIR or GCMS (\$\$)





# Sympatholytic

- Acute (immediate, short-term) effects
- Profound sedation
- Low blood pressure
- Slow heart rate
- Weak or absent reflexes
- Chronic (gradual, long-term) effects
- Severe skin wounds
- Anemia
- Dysglycemia (usually hyper)

fight-or-flight nervous system

breaks down/suppresses





## Wounds

- The most striking aspect!
- Consistently described as:
  - Forms a thick eschar as they heal
  - Develop in areas other than where the patient injected
  - Large and difficult to heal
  - Necrotic areas are commonly reported
  - Granular in appearance, burn-like
- Can also involve loss of fingers/toes
- Appears vascular, but we don't really know
- Secondary bacterial infection all but guaranteed for people experiencing homelessness





# Chronic Issues

- With chronic, ongoing use of xylazine...
- Anemia (unclear cause)
  - Usually noticed as:
    - Weakness/fatigue
    - Brain fog
    - Irregular heartbeat
    - Feeling cold easily
- Blood sugar irregularities
  - Usually hyperglycemia
  - Unclear if transient
  - Has been noted in vet literature
- Loss of some autonomic tone
  - Reports of dulled reflexes, incontinence

#### Xylazine poisoning: a systematic review

Noah S. Ball, Brittany M. Knable, Taylor A. Relich, Allyson N. Smathers, Michael R. Gionfriddo, Branden D. Nemecek, Courtney A. Montepara, Anthony J. Guarascio, Jordan R. Covvey & David E. Zimmerman

To cite this article: Noah S. Ball, Brittany M. Knable, Taylor A. Relich, Allyson N. Smathers, Michael R. Gionfriddo, Branden D. Nemecek, Courtney A. Montepara, Anthony J. Guarascio, Jordan R. Covvey & David E. Zimmerman (2022): Xylazine poisoning: a systematic review, Clinical Toxicology, DOI: <a href="https://doi.org/10.1080/15563650.2022.2063135">10.1080/15563650.2022.2063135</a>

To link to this article: https://doi.org/10.1080/15563650.2022.2063135



# Let's Talk Sedation!

- I don't just mean sleepy...
- I mean "can't move at all for hours"
- Position matters
- Also a fall risk!
  - Discourage standing when using
- Reported
  - Muscle damage
  - Nerve damage
  - Rhabdomyolysis
- Harm reduction for xylazine must include watching out for others who are sedated, and moving them regularly!





## Harm Reduction

- HR for sedation
  - Never use alone!
  - Sit or lay down when using
  - Watch out for your friends who are nodding (unconscious) longer than normal
  - Make sure breathing and heart rate are adequate,
     and then –
  - Don't allow people to nod in weird positions
  - Put people into the recovery position (ideally)
  - Roll from one side to the other every hour or so
  - Place padding under bony places heels, hip, shoulder, ankles, etc.
  - Teach on signs/symptoms of rhabdomyolysis





# Teamwork = Dreamwork

- We know very little about xylazine in humans, especially chronic use
- We must work together, share ideas, successes, and failures
- We will spend years waiting for bench research







# I want to hear from you!

Claire Zagorski, MSc, LP
The University of Texas at Austin
claire.zagorski@austin.utexas.edu
@clairezagorski

